# Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer

> **NCT01047891** · PHASE2 · COMPLETED · sponsor: **JSehouli** · enrollment: 174 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01047891
- **Lead sponsor:** JSehouli
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2015-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047891, "Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01047891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*